Introduction
addition of virus. For quantifying end point titers, samples were diluted four-fold from 1:40 to 144 1:10240 and tested in duplicate; final titers were estimated by probit regression. 145 For seroprevalence studies, test viruses were DENV-1 16007 (DHF case from Thailand, 146 1964), DENV-2 16681 (Asian I genotype; DHF case from Thailand, 1964) , DENV-3 IQD1728 147 (DF case from Peru, 2002) , and DENV-4 1036 (DF case from Indonesia, 1976) . DENV-2 16681 148 (Asian genotype) was selected for the seroprevalence assays because previous experiments in our 149 laboratory showed that this strain minimized a cross-reactive response from DENV-1 infection 150 [9] . For comparing antibody titers against Am-DENV-2 and AA-DENV-2 genotypes, viral 151 strains were IQT2124 (American genotype, Iquitos, 1995), IQT2913 (American genotype,
152
Iquitos, 1996), NFI1159 (American/Asian genotype, Iquitos 2010), and NFI1166 153 (American/Asian genotype, Iquitos, 2010).
154
Febrile surveillance. Clinic-based surveillance was conducted as described previously [17] .
155
Briefly, participants 5 years of age or older were enrolled when reporting to outpatient clinics or 156 hospitals in Iquitos within 7 days of onset of symptoms (fever, plus one or more other symptoms, described [17] . Based on clinic-based febrile surveillance, 84% (n=433) of all DENV isolates 166 during the 2010-2011 epidemic were DENV-2, 13% (n=69) were DENV-4 and 3% (n=13) were 167 DENV-1. cases is determined by the age structure of the population and at least three key epidemiological 178 processes: immunity, the force of infection (risk of exposure) and the development of clinical 179 symptoms. Given age-specific profiles for each of these and the age structure of the population, 180 the expected age distribution of cases can be inferred. If we consider the scenario of a novel 181 pathogen invading a completely susceptible population with no age dependence in risk of 182 exposure or manifestation of disease, then the age distribution of cases would mirror the age 183 distribution of the population. By contrast, the re-introduction of an immunizing pathogen should 184 result in a shift of cases to lower age groups who have no prior exposure and, therefore, no 185 protection. We would expect this shift would be less marked, however, if immunity were To compare the observed age distribution of DENV-2 cases in clinics and hospitals to the 188 age distribution we computed an expected age distribution of cases based on: (1) the total 189 number of observed cases (say N), (2) the age distribution of individuals who appeared at the 190 clinics and hospitals with a febrile illness [17] and participated in the febrile surveillance studies 191 in past years, and (3) age-based distribution of DENV-2 neutralizing antibodies in the months 192 preceding the epidemic. From (2) and (3) we computed the expected probability that the next 193 case that appears in the clinics with DENV-2 will be of a particular age (for each age group).
194
Specifically, for each age group, we found from (2) what percent of that age group is still 195 susceptible to DENV-2 (say, for age group i, p i ) and from (3) we found what percent of those 196 who appeared at a clinic or hospital were from that age group (say, for age group i, ai). Letting qi 197 be the probability that the next DENV-2 case that appears at a clinic or hospital is of age group i, 198 we have:
This equation is based on the assumption that an individual of any age is equally likely to 201 become infected. By multiplying these probabilities by the total number of DENV-2 cases 202 identified at the clinics and hospitals, we arrive at the expected number of cases by age that 203 would have been expected if the patterns of age at time of infection were identical during the 204 epidemic as compared with before the epidemic (specifically, for age group i, qi x N). children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Overlapping age distributions suggest that there were no gross age-dependent differences in risk 628 for infection within the study population. 
